CCL11 and lung cancer: As changes in circulating eotaxin-1 can be detected soon after one cycle of PD-1/PD-L1 blockade treatment, this may be useful for monitoring clinical outcomes in lung cancer patients receiving PD-1/PD-L1 blockade therapy [25].